维奥欣对抗阿霉素心脏毒性作用的初探

Efficacy of weiaoxin against cardiac toxic action of adriamycin in treating malignancy

目的:评价阿霉素化疗合用维奥欣治疗恶性肿瘤的疗效及安全性。方法:31例恶性肿瘤患者随机被分为两组。治疗组15例于化疗前2周开始口服维奥欣,160 mg,3次/d,共10周,用含阿霉素的方案作联合化疗,每4周为1 个周期,共2个周期。对照组16例单用阿霉素化疗方案。结果:治疗组和对照组近期疗效总有效率分别为33. 33%和37. 50%(P>0. 05) ,差异无显著性;两组治疗后心电图异常改变分别为6. 67%和43. 75%(P<0. 05) ,心功能减低分别为0和31. 25%(P<0. 05) ,差异均具有显著性。结论:维奥欣可以降低阿霉素治疗恶性肿瘤的心脏毒性,维持心功能,且不影响抗肿瘤效果。

Objective： To evaluate the efficacy of adriamycin （ADM） and weiaoxin for malignancy. Methods： A total of 31 patients with malignancy were randomized into two groups： weiaoxin group, 15 patients received treatment of weiaoxin with 160 rag, 3 times/d, for 10 weeks. Control group, the other 16 patients received ADM only. Results：Overall efficiency rate was 33.33% in weiaoxin group, and 37.5% in control group （P〉0.05）; the abnormity rate of electrocardiogram was 6.67 % in the weiaoxin group, and 43.75% in the control group （P〈0.05）; the heart function reduced rate was 0 in weiaoxin group, and 31.25% in control group （P〈0.05）. Conclusion： Efficacy of adria mycin and weiaoxin for malignancy were not effecting the afficacy of adriamycin alone in the near future, hut relief the toxicity of adriamycin for heart.